By Editorial TeamAI in cardiology has huge potential, but getting it paid for and widely used is another story entirely. If you’re a clinical advisor or a VC looking at the next batch of AI-native health companies, the only way to separate the real breakthroughs from the marketing fluff comes down to one thing: how serious they are about their clinical trial design.
Two Kinds of Evidence: Prospective vs. Retrospective Trials
When it comes to clinical validation, the quality of the evidence is everything. The difference between a prospective and a retrospective trial isn’t a small technicality, it directly affects the credibility and eventual commercial success of any cardiac AI tool. Retrospective studies are fast and cheap because they just re-analyze old data, but they’re full of potential bias (like selection bias) since you can’t control how the original data was collected. Good luck convincing a health plan or the FDA to get on board with a new device based on that kind of look-back evidence. They’re getting very skeptical.
Prospective trials are the opposite. You design them from scratch to test a specific hypothesis, defining your patient groups, interventions, and what you’re measuring before you even start collecting data, which minimizes bias and lets you actually draw a line from cause to effect. For an AI company, that means you need a protocol spelling out exactly how the AI fits into the workflow, how you’ll measure its output, and how you’ll track patient outcomes long-term. This is the only methodology that really stands up to the scrutiny needed for medical device validation, which is your only path to getting reimbursed and earning trust from clinicians.
The American Heart Association (AHA) has been hammering this point home for a while, especially with recent guidance like their November 2025 advisory on evaluating AI: digital health tools need strong, prospective validation. It’s not optional for tech that affects patient care AHA statements on digital health validation. That position from the AHA directly influences what payers will cover and how regulators think, so every investor has to pay close attention.
How Trial Design Actually Impacts the Business
A quick search on ClinicalTrials.gov tells you everything you need to know. Sure, a lot of early-stage companies use retrospective data for a quick proof-of-concept, but the ones that are serious about getting to market and growing always invest in prospective trials. Just look at Cleerly. They’re all-in on using AI for plaque analysis, and they’ve backed it up by running big, prospective trials like TRANSFORM and PARAMOUNT to prove their tech can find and characterize CAD better than the old methods Cleerly clinical trial information on ClinicalTrials.gov. When you see a company committing to large, multi-center studies like that, it’s a huge signal that they have a real long-term commercial plan and they know what it takes to get through the regulatory and reimbursement gauntlet.
Even when the FDA gives you a fast-track like the Breakthrough Device Designation that Cleerly got for its CAD Staging System, they still demand solid validation data. If you want to get a Software as a Medical Device (SaMD) through a 510(k) clearance or De Novo classification, your evidence has to be rock-solid on safety and effectiveness. Retrospective analyses can help you get started, but they almost never get you across the finish line for approval or payer coverage. Payers, especially, will tear apart your data. They want to see proven clinical utility and cost-effectiveness from a well-run prospective trial before they’ll even consider a new CPT code, like the Category I code Cleerly secured for its analyses, effective January 2026, or NTAP eligibility.
The money part is simple: a cardiac AI tool backed only by looking at old data faces a much harder, longer road to making money. Health systems will hesitate to integrate a tool they see as unproven, and payers won’t want to cover something without clear evidence of benefit from a controlled, real-world study. This is how you get a “zombie company”, one that lands some seed funding based on a cool idea but can’t scale because it never generated the hard clinical evidence to back it up.
What Investors Should Look For
For VCs and clinical advisors, digging into a startup’s clinical pipeline is the most important part of due diligence. Here’s what to screen for:
- Prospective Trials First: Look for companies that are already running or have finished prospective, randomized controlled trials (RCTs). That’s the gold-standard evidence for clinical utility you need for regulatory approvals and getting paid.
- Ask About Algorithmic Drift: A big proprietary dataset is great, but how are they handling algorithmic drift over time? Ask if they have a real GMLP (Good Machine Learning Practice) framework and a PCCP (Predetermined Change Control Plan). It shows they’re thinking ahead about model management and compliance.
- Know Their Regulatory Plan: They need a clear plan for getting FDA clearance (510(k) vs. De Novo) and the clinical data to back it up. A company that’s already secured a Breakthrough Device Designation, for instance, is sending a strong signal that they’re serious about the validation process.
- Check the Reimbursement Angle: Is there an existing CPT® code they can use, or a clear path to getting one? The ability to get paid, which is directly tied to the strength of their clinical evidence, makes or breaks commercial adoption.
- It’s More Than Just the Algorithm: A fancy algorithm means nothing if you can’t prove it helps patients. The best AI-native companies build clinical validation into their product development from day one. It’s not some final step they tack on at the end.
Spending the money on a prospective clinical trial is expensive, but it’s a direct investment in long-term commercial success. It shows a company is serious about proving its tech works, dealing with the regulators, and actually getting their tool used in hospitals and clinics. Without it, even the smartest AI solution is just a cool piece of tech with no real-world impact and no path to revenue.
A Note on Sources
This analysis comes from reviewing active trials on ClinicalTrials.gov and looking at public statements from groups like the American Heart Association, including their recent push for digital health certification and AI monitoring guidelines from late 2025. The insights here are based on examining those trial designs and what they mean for the business side of cardiac AI companies. When a company like Cleerly is mentioned, it’s based on their publicly available information about their clinical strategy. ClinicalTrials.gov database
Frequently Asked Questions
What is the significance of Cleerly’s clinical trial strategy for cardiac AI adoption?
Cleerly’s commitment to prospective clinical trials, such as TRANSFORM and PARAMOUNT, is crucial for validating its AI-driven plaque analysis technology. This strategy aligns with regulatory and reimbursement requirements, as evidenced by its FDA Breakthrough Device Designation, 510(k) clearance for Cleerly ISCHEMIA, and a CPT Category I code for its AI-QCT analyses.
Why are prospective clinical trials considered more valuable than retrospective studies for cardiac AI solutions?
Prospective trials are designed to test specific hypotheses before data collection, minimizing bias and strengthening causal inference, which is critical for establishing credibility and generalizability. Retrospective studies, while quicker, are prone to biases and are increasingly viewed with skepticism by health plans and regulatory bodies for novel technologies.
How is the American Heart Association (AHA) influencing the adoption of cardiac AI?
The AHA emphasizes robust clinical trial standards, particularly prospective validation, for digital health interventions. They launched a “Digital Health in Cardiac Care” certification program and issued advisories urging clear rules for AI use in patient care, highlighting the need for rigorous local validation and bias assessment.
What are the regulatory and reimbursement implications of a strong clinical trial design for cardiac AI companies?
A strong prospective clinical trial design is paramount for securing regulatory approvals like FDA 510(k) clearance or De Novo classification, as well as for achieving widespread payer coverage. Payer organizations scrutinize clinical utility and cost-effectiveness demonstrated through well-designed trials before issuing CPT codes or establishing NTAP eligibility.
